The global radioligand therapy market was valued at
Global Radioligand Therapy Market to Reach $16,658. 4 Million by 2031. ...
Source: globenewswire.com
Page 13 - Technologies Munich News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Technologies Munich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Technologies Munich Today - Breaking & Trending Today
ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer
ITM to supply Advanced Accelerator Applications on an industrial scale with its high-quality n.c.a. lutetium-177 as core component of the newly approved radiotherapeutic, Pluvicto
Source: itnonline.com
ITM Isotope Technologies Munich SE: ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer
ITM to supply Advanced Accelerator Applications on an industrial scale with its high-quality n.c.a. lutetium-177 as core component of the newly approved radiotherapeutic, PluvictoTM ITM Isotope
Source: finanznachrichten.de
Novartis' Pluvicto prostate cancer therapy approved by FDA
Novartis has received a boost to its cancer therapeutics after FDA approved Pluvicto™ and diagnostic Locametz® for advanced prostate cancer.
Source: europeanpharmaceuticalreview.com
ANSTO extends partnership with ITM
The Australian Nuclear Science and Technology Organisation has secured a long-term IP and technology license agreement with a German-based company.
Source: lawyersweekly.com.au